ISELIN, N.J., August 14, 2026
Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg) following its FDA approval for the treatment of neovascular or wet age-related macular degeneration (wet AMD). The company is focusing its current efforts on building the commercial infrastructure required to support a planned U.S. launch before the end of calendar 2026. Key activities include expanding payer engagement, reimbursement planning, pricing strategy, commercial supply capabilities and medical affairs, while developing a specialized commercial organization focused on the retina market. Outlook Therapeutics said LYTENAVA addresses a significant need in the U.S., where bevacizumab is already widely used in ophthalmic practice, but historically has not had an FDA-approved ophthalmic formulation specifically for wet AMD. The company believes the FDA-approved product could provide physicians and retina practices with a standardized ophthalmic bevacizumab option supported by the regulatory approval process.
Outlook Therapeutics Builds Commercial Infrastructure for LYTENAVA
A major focus for Outlook Therapeutics is preparing the LYTENAVA U.S. launch strategy around access, reimbursement and adoption by retina practices. The company has established customer segmentation and targeting plans intended to prioritize practices with the greatest potential for early adoption. Outlook Therapeutics is also expanding its commercial team with professionals experienced in retina care, product launches and the anti-VEGF treatment market. The company said its go-to-market strategy is being developed in response to the increasingly competitive wet AMD landscape, including the evolving biosimilar environment and affordability considerations. To support reimbursement following commercialization, Outlook Therapeutics plans to submit an application for a permanent Healthcare Common Procedure Coding System (HCPCS) code by October 1, 2026. The company is also scaling commercial supply capabilities to ensure product availability as launch activities progress. These efforts are central to the company’s strategy of achieving broad market access and supporting physicians and patients following the U.S. introduction of LYTENAVA.
LYTENAVA Commercial Expansion Extends Beyond the United States
Outlook Therapeutics is also continuing to expand the commercial availability of LYTENAVA in international markets, with commercialization activities underway in Germany, Austria and the United Kingdom. The company is preparing for a potential launch in the Netherlands later in 2026 following its regulatory submission, while its Swiss partner Mediconsult is leading regulatory and commercial preparations for an anticipated Switzerland launch in 2027. In the United States, LYTENAVA is positioned as an ophthalmic formulation of bevacizumab specifically approved by the FDA for wet AMD, giving the company an opportunity to address an established treatment market where anti-VEGF therapies are widely used. LYTENAVA works by targeting vascular endothelial growth factor (VEGF-A), helping inhibit processes involved in abnormal blood vessel growth and vascular permeability that contribute to vision loss in wet AMD. The company’s immediate priority, however, remains translating the regulatory milestone into a successful commercial launch through market access, physician engagement, reimbursement and supply readiness.
Advertisement
Outlook Therapeutics Reports Financial Position as Launch Approaches
Alongside its commercial update, Outlook Therapeutics reported its third-quarter fiscal year 2026 financial results for the period ended June 30, 2026. The company recorded a net loss attributable to common stockholders of $20.3 million, compared with $20.2 million in the same quarter of the prior year. Adjusted net loss was $10.9 million, compared with $15.8 million in the third quarter of fiscal 2025. Outlook Therapeutics reported $11.2 million in cash and cash equivalents as of June 30, 2026, before proceeds from a subsequent public offering. In August 2026, the company announced an offering that generated approximately $51.1 million in net proceeds, providing additional resources as it moves toward commercialization. Management has estimated that LYTENAVA could potentially exceed $500 million in annual U.S. sales by 2030, although this remains a company projection rather than an established commercial outcome. With FDA approval secured, the key near-term focus for Outlook Therapeutics is now execution of its U.S. launch plan and expansion of patient access to LYTENAVA.
Source: Outlook Therapeutics press relese
